Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Helperby Therapeutics
Helperby Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
How can we save medicine from superbug disaster?
Two leading research teams to collaborate on new fast track antibiotic therapies, with an aim to bring new sophisticated combination therapies to market in a much-reduced timescale
Ingredients
Two of the world’s leading research teams to collaborate on new fast track antibiotic therapies
Aiming to bring new sophisticated combination therapies to market in a much reduced timescale
Regulatory
Treatments to solve global antibiotic crisis may reach the market in 2020
Helperby Therapeutics has developed the first sustainable solution to combat all three deadly critical priority pathogens named by World Health Organisation (WHO)<sup>1</sup>
Research & Development
Helperby Therapeutics and Cadila sign antibiotic drug resistance agreement
Cadila will take a new Helperby compound through Phase III trials, approvals and into commercialisation
Subscribe now